GLP-1 research compound

Semaglutide — Research Reference Guide

Semaglutide is one of the most studied GLP-1 receptor agonists in modern endocrinology research. This reference summarises what laboratory teams typically review before sourcing a research-grade lyophilised peptide.

What semaglutide is

Semaglutide is a long-acting GLP-1 analogue first characterised in metabolic-research literature for its prolonged receptor occupancy and once-weekly pharmacokinetic profile. As a research compound it ships as a lyophilised powder for reconstitution with bacteriostatic water.

Typical research handling

Lyophilised semaglutide is stored refrigerated; once reconstituted, most laboratories follow a 28-day in-use stability window with strict cold-chain handling. Cross-reference COA values for purity, peptide content and water content before any experimental protocol.

Why purity matters

HPLC purity below 99% can indicate truncated sequences or process residues. Every Regena batch ships with an independent COA and mass-spec confirmation — see the lab reports page for the latest batch documentation.

Related GLP-1 research compounds

Researchers comparing receptor selectivity often look at tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist). The Peptide Library lists all three with current batch data.

Frequently asked questions

Is this medical advice?+

No. All content is educational and intended for in-vitro research reference only. Nothing on this page constitutes a recommendation for human use.

How is semaglutide stored?+

Lyophilised vials are typically held at 2–8°C. Reconstituted product is kept refrigerated and used within the window stated on the COA.

Where can I review the COA?+

Every batch COA is published on the lab reports page and linked from each variant in the Peptide Library.

Continue your research

Trusted reference supplier · Verified across review platforms